Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL5702541 | 0.83 | LMNA (0.43) | LMNAMEN1KMT2AACHETDP1 | |
| P-Cresol SCHEMBL1904230 | 0.80 | ACHE (0.59) | LMNAMEN1KMT2AACHETDP1 | |
| Tromethamine SCHEMBL5564327 | 0.80 | ACHE (0.59) | LMNAMEN1KMT2AACHETDP1 | |
| Tromethamine SCHEMBL7181961 | 0.78 | LMNA (0.43) | LMNAMEN1KMT2AACHETDP1 | |
| Tromethamine SCHEMBL7101299 | 0.78 | ALDH1A1 (0.42) | LMNAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL193486 | 0.75 | — | — | |
| Tromethamine SCHEMBL1290395 | 0.75 | CES2 (0.42) | LMNAMEN1KMT2ACES2CES1 | |
| Tromethamine SCHEMBL4329786 | 0.75 | NQO1 (0.50) | KMT2ATDP1ALDH1A1 | |
| SCHEMBL15362252 | 0.74 | CYP1A2 (0.41) | LMNAMEN1KMT2AACHES1PR1 | |
| Bromide SCHEMBL7197581 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382856-A1 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-30 | — | — | US | disclosed |
| EP-4238961-A1 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-09-06 | — | — | EP | disclosed |
| US-8242217-B2 | Epoxy resin curing agent, process for preparing the same, and epoxy resin composition | SHOWA DENKO K.K. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100273940-A1 | EPOXY RESIN CURING AGENT, PROCESS FOR PREPARING THE SAME, AND EPOXY RESIN COMPOSITION | SHOWA DENKO K.K. (JP) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382856-A1 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | INMT, TDO2, HNMT | LMNA 2502/4885MEN1 3840/4885KMT2A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.